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Nowadays cardiovascular disease remain globally the leading cause of mortality. 
Coronary artery disease is the predominant clinical entity related to fatal cardiovas-
cular events, while its development is mostly associated with progressive atheroscle-
rosis of the vessels combined with gradual vascular calcification. It is well described 
and understood that vascular calcification is strongly associated with the occurrence 
of CVD and increased mortality rates. Therefore, it is essential to understand the 
metabolic pathways leading to its formation in order to develop effective therapies. A 
group of vitamin-k dependent proteins seems to play a significant role on the preven-
tion of the arterial wall. Several past studies have shown that in cases of vitamin-k 
deficiency the process of vessel calcification is accelerated. Vitamin-k depletion and 
high levels of uncarboxylated and dephosphorylated forms of the aforementioned 
proteins are considered as important factors that contribute significantly to this 
rapid progression. Promising studies are giving the stimulus for further research in 
the field of vitamin-k supplementation and the suspension of vascular calcification.
Keywords: vitamin K, deficiency, vitamin-K dependent proteins, vascular 
calcification, coronary artery disease
1. Introduction
Cardiovascular diseases are the leading cause of mortality worldwide. Their 
constant increasing rate is attributed to many factors as the adoption of poor 
dietary habits and sedentary lifestyle accompanied in some cases with hereditary 
background. The so-called Western way of living has led also to the rise of other 
diseases such as dyslipidemia, hypertension, obesity, diabetes mellitus and chronic 
kidney disease, which are the main risk factors of CVD. Those conditions are 
mainly responsible for the rapid progression of vessel’s atherosclerosis and plaque 
formation. Intimal calcification of large vessels is the main effect of those disor-
ders responsible for plaque’s progression. However, atherosclerosis is not the only 
factor. Vascular calcification is another major and independent risk factor strongly 
related with the development of vessel plaque leading to CVD [1]. It is a chronic 
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and multi-factorial procedure related mainly with disorders such as chronic kidney 
disease and diabetes mellitus [2]. The metabolic pathways which are responsible for 
the progression of vascular calcification is not well-established and consequently 
treatment remains a challenge. Media arterial layer is the target area of calcification 
and can involve all vessel sizes regardless of the concurrence of atheromatic plaque 
[3]. The negative effect of this procedure can gradually lead to the development of 
valvural heart disease and coronary artery disease (CAD).
Matrix degradation and modification is the main reason of medial arterial 
calcification. Matrix Gla protein (MGP), Gla rich protein (GRP) and growth 
arrest specific gene-6 (Gas-6) are a group of vitamin-k dependent proteins that 
is considered to effectively inhibit the progression of vascular calcification. For 
example, in cases of vitamin-k deficiency, glutamic acid residues do not convert 
to the amino acid γ-carboxyglutamic acid residuals (Gla) which is a vital part for 
the normal function of MGP. Consequently, inactive forms of MGP (dp-ucMGP) 
accumulate in calcified tissues such as the blood vessels. Past studies have proposed 
ucMGP as a potential marker of vitamin-K deficiency, vascular calcification and 
cardiovascular disease [4]. Other trials have showed that patients under treatment 
with vitamin-k antagonists (VKAs) had higher scores of vascular calcification 
compared to a group of controls. Animal trial connected the administration of 
VKAs with an accelerated progression of medial calcification. On the other hand, 
when high doses of vitamin-K were administered, calcification lesions started 
slowly to improve [5]. Perspectives about the benefit of vitamin-K administra-
tion in specific population remain controversial, and therefore further research is 
required in this domain.
2. Vitamin-K dependent proteins
The correlation between low vitamin-K levels and rapid progression of vascular 
mineralization is supported by researchers in the past [6]. The pathophysiological 
pathways that justify such claims involve a group of vitamin-K dependent protein 
and calciprotein particles. Those proteins are the matrix Gla protein (MGP), 
gamma-carboxylated Gla-rich protein (GRP) which are both considered as strong 
inhibitors of vascular calcification and the growth specific arrest gene-6. Matrix 
Gla protein (MGP) is a vitamin-k2 dependent protein which is secreted by many 
cells, including the vascular smooth muscle cells (VSMC) and has high affinity to 
calcium crystals. Its effect on atherosclerotic plaque may probably derive from the 
blocking of calcium accumulation. It’s present in bones and cartilage, in kidneys 
but also in blood vessels, endothelium and coronary artery. Matrix Gla protein 
prevents from the calcification development in soft tissues such as the blood vessels. 
Additionally, its preventive effect is exerted by inhibiting the bone morphogenetic 
protein-2 and 4 (BMP-2, BMP-4). This effect is of outmost importance because it 
prevents the VSMC from the transdifferentiation into osteoblasts like-cells which 
lead into progressive calcification of atherosclerotic plaques. In order to exert 
its effect, MGP has to be synthesized locally in the VSMCs. Vitamin-k2 is used 
as co-factor to its formation through the post-translational γ-carboxylation and 
phosphorylation of inactive MGP [7]. Carboxylated MGP (cMGP) is the active 
protein form responsible for the prevention of the calcification of the arterial 
wall [8]. MGP’s expression from the VSMCs and the endothelium may give us the 
opportunity to measure its circulating levels. As it was mentioned before, cMGP 
has high affinity to calcium crystals and binds strongly to them preventing from 
their accumulation into the arterial wall. Considering that cMGP could evolve into 
a very promising biomarker for the prognosis and the progression of calcification 
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as well as a prognostic factor to severe cardiovascular outcomes [9]. On the other 
hand, it should be mentioned that inactive forms of MGP have been associated with 
accelerated rate of vascular calcification but also with increased mortality [10]. 
Whereas the active form of MGP is both carboxylated and phosphorylated, the 
inactive forms have not undergone one of those two metabolic steps or both of them 
(uncarboxylated, dephosporylated MGP, dp-ucMGP). cMGP is the only factor that 
under specific conditions may promote the reversal of vascular calcification [11]. 
It is worth mentioning that calcified arteries have high concentrations of MGP and 
the severity of such lesions was related to MGP serum levels [12]. Gla rich proteins 
is another vitamin K dependent protein which is present in both bone and cartilage 
and also has high affinity to calcium. High concentrations of γ-carboxylated GRP 
have been observed in individuals with increased vascular calcification. However, 
suggested data derive mainly from animal studies and its functionality in humans is 
not well established. Calciprotein particles are particles that prevent from vascular 
calcification by blocking the formation of the calcium/phosphate crystals. These 
particles also contain high levels of MGP and GRP, so in cases of vitamin-k defi-
ciency, their effect may be impaired. Vascular smooth muscle cells excrete also the 
growth arrest specific gene 6 protein (Gas-6) which is one of the stimulating factors 
of their growth. It exerts its preventive effect through several pathways. Initially it 
stimulates the bcl-2 anti-apoptotic protein which is responsible for the inhibition 
of caspase-3. Caspase-3 is a crucial protein for the pro-apoptotic cell procedure, so 
through that way Gas-6 protects VSMCs from transdifferentation into cells with 
osteoblast-like effects. Apoptotic cells could be used as substrate for the develop-
ment of constant inflammation and excessive calcification. Thus, Gas-6 through 
this way Gas-6 prevents the arterial from this process. However, in order to exert 
Figure 1. 
Summary of the effect of vitamin K deficiency on vascular calcification. Abbreviations: BMP-2, bone 
morphogenetic protein-2; VSMCs, vascular smooth muscle cell.
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its effects Gas-6 needs γ-carboxylation a process in which vitamin-k is a necessary 
co-factor [13]. Taking all that into consideration, Gas-6 is vitamin-K dependent and 
very important factor, against the VMSCs apoptosis and the progression of calcified 
plague. In cases of vitamin-k deficiency the lack of Gla proteins affect negatively the 
growth of VSMC [14] (Figure 1).
3. Postmenopausal women, vitamin-k and vascular calcification
In past studies it was also observed that post-menopausal women with osteo-
porosis had increased rates of arterial calcification [15]. Based on that, researchers 
have investigated the potential correlation of vitamin-k status, bone formation 
rate and vascular calcification of post-menopausal women. Initially, lower bone 
formation rate in parallel correlation with low levels of serum vitamin-k. The 
same also applies for the increased frequency of vascular calcification observed 
in post-menopausal women [16]. Concerning, the lower bone mass of post-
menopausal women, it seems that vitamin-k levels and osteocalcin induced 
remodeling bone process are closely related. Though not with the same metabolic 
way to vascular calcification but in both situations vitamin-k is necessary [17]. It is 
important to mention that few trials, evaluated the potential benefit of vitamin k2 
supplementation in post-menopausal women with aortic calcification and osteo-
porotic lesions. According to the authors, calcified lesions were at least sustained 
or in some cases decreased. However, these beneficial effects were observed in 
individuals that received vitamin-k2 supplementation but not vitamin-k1 [18]. 
Finally, results from the study of Gast et al. in this group of patients, have showed 
that vitmamin-k2 had the greatest preventive effect in CAD [19]. There are data 
that suggest that osteoporotic women are on higher risk of cardiovascular disease 
compared to match-aged non-osteoporotic individuals. These evidence imply 
that this difference occurs due to increased vascular calcification of both large 
vessels and coronary artery in those patients. Vitamin-k2 may have an essential 
role both to bone formation via its effect on osteocalcin as well as to the reduc-
tion of vascular mineralization. Further and larger studies are needed in order 
to assess the potential benefit of vitamin-k2 supplementation in both bone mass 
loss, atherosclerotic progression and prevention of cardiovascular disease in this 
specific population [20].
4. Vitamin-k-antagonists and vascular calcification
Vitamin-k antagonists are oral anticoagualants that reduce the levels of vitamin-
k by interfering in vitamin’s recycle. They essentially inhibit vitamin-k reductase 
complex-1 and consequently reducing active vitamin-k reserves. Thus, they prevent 
from the formation of blood clots. Nevertheless, vitamin-k depletion in serum has 
some detrimental effect on many sequences of steps in metabolic pathways like 
those mentioned before. Taking that in mind, previous studies have demonstrated 
the negative effect of VKAs on the progress of vascular calcification [5]. Win et al. 
examined the potential benefit of apixaban administration in patients with atrial 
fibrillation in terms of the atherosclerotic plaque progression. Study results showed 
that apixaban administration was associated with slower plaque progression as well 
as lower calcium scores compared to warfarin treated group. Taking into consider-
ation the usual co-existence of atrial fibrillation and coronary artery disease, apixa-
ban could be a preferable choice in patients with atrial fibrilation not only for the 
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prevention of thromboembolic events but also to slow down coronary plague pro-
gression and prevent from fatal cardiovascular events [21]. Accordingly, outcomes 
from a trial that compared the use rivaroxaban against warfarin have also indicated 
the beneficial effect of NOAGs into the slower plaque progression arterial calcifica-
tion [22]. Therefore, in cases of individuals with established CAD or high level of 
vascular atherosclerosis in need for anticoagulation, the physician should choose 
wisely the appropriate treatment. These data suggest the preferable choice of NOACs 
instead of VKAs though further studies are needed for more robust results. However, 
what about patients that are in need for VKAs coagulation, or the use of NOACs is 
contraindicated? Such dilemmas are common in clinical practice and therefore the 
presence of clearly defined guidelines is essential.
5. Chronic kidney disease, vitamin-k status and vascular calcification
Chronic kidney disease is strongly associated with the presence of increased 
cardiovascular risk. The most frequent cause of death in this population is coronary 
artery disease as well as stroke events. Hypertension, dyslipidemia, diabetes mel-
litus, which are common comorbidities in patients with renal failure, are important 
factors that can lead to excessive atherosclerosis and the development of CVD. 
Moreover, vascular calcification is also excessive in patients with chronic kidney 
disease (CKD) and so it constitutes an independent risk factor for the develop-
ment of CVD [23]. Age, time on hemodialysis, persistent hyperphospahetamia and 
hypercalciemia are some of the causes of accelerated vascular calcification. High 
calcium and phosphate levels are associated with the deposition of hydroxyapatite 
into the arterial wall [24]. Whereas the presence of intimal calcification, which 
is related mainly to large vessels, is almost the same between individuals with or 
without end-stage renal disease, this is not the case for median calcification of the 
arterial wall. For example, aorta calcification is worse in patients with renal disease 
compared to those without. Aorta calcification increases arterial stiffness, which 
consequently aggravates the present hypertension and finally contributes to the 
development or the deterioration of a pre-existing left ventricular hypertrophy and 
left ventricular insufficiency. Patients with end-stage renal disease have increased 
vascular calcification compared to non-CKD individuals, especially those that are 
under hemodialysis [25]. Coronary artery calcification is common among older 
patients with CKD. However past studies have also showed that younger individuals 
with end-stage renal disease have also a high percentage of vascular calcification as 
well as coronary artery calcification [26]. Using high resolution computed tomog-
raphy; researchers have proved that coronary calcification was higher in young 
adults that were on dialysis compared to those that were not. At this moment, the 
main treatment approach against the vessel mineralization of CKD patients is the 
strict regulation of calcium and phosphate balance. Additionally, clinician focus 
their attention to better treatment management of concomitant disorders that affect 
atherosclerotic plaque, such as diabetes, dyslipidemia and smoking cessation. Even 
though there is no strong evidence that support the administration of agents that 
inhibit calcification, it is easy to understand that those interventions might play a 
crucial role to the prevention of CVD in CKD-individuals. In a microenvironment 
of constant inflammation, vascular smooth cells are gradually transformed in 
osteoblasts like-cells promoting then the development of medial artery calcifica-
tion. This process is mediated by multiple proteins and is facilitated by the presence 
of systemic or local inflammation. The latter is of outmost importance for the 
reason that macrophages excrete among others, matrix-metalloproteinase which 
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lead to the apoptosis of elastic fibers and thus promote vascular calcification. In 
addition, vitamin k-dependent matrix Gla protein and Gia-rich protein are both 
important for vascular calcification. As it was mentioned before, low levels of those 
proteins have been associated with increased rate of calcification and development 
of cardiovascular disease. Several studies in the past have proved the increased 
coronary artery calcification in CKD-individuals by calculating the number of 
vessel calcifications using high resolution computed tomography. According to the 
study of Holden et al. in patients with CKD and/or end-stage renal disease vitamin-
K deficiency is very common. It is possible that this outcome has some extra effect 
on the progressive calcification of these patients [27]. At this point, treatment in 
order to delay the progression of vascular calcification in ESRD and CKD patients 
targets to the regulation of calcium and phosphate. However, dietary advice in order 
to prevent hyperkaliemia or hyperphospatemia leads to the avoidance of food rich 
in vitamin k, inducing the existing deficiency. A recent study with hemodialysis 
patients have studied the ffect of vitamin-k supplementation on the plasma levels of 
ucMGP, uncarboxylated osteocalcin and PIVKA-II. The results were very promis-
ing, because have showed a significant decrease of the inactive form of MGP and 
also proved the vitamin-k deficiency in this specific population. The outcomes of 
this study may be the beginning of future randomized controlled trials that will 
evaluate the effect of vitamin-k supplementation on vascular calcification of CKD 
patients [28]. Respectively, another study by Oikonomaki et al. in hemodialysis 
patients have demonstrated the reduction in uc-MGP levels after 1-year of vitamin-
k2 supplementation but the progression of vascular calcification remained the same 
between studied groups [29]. It is possible that only vitamin-k supplementation 
is not enough in order to overt calcification. This process in such individuals is so 
multi-factorial that need a comprehensive treatment approach that will slow the 
progression. Further studies are needed in order to clarify the benefits of vitamin-k 
supplementation in ESRD or CKD patients.
6. Vitamin-k and coronary calcification
Vascular calcification and especially coronary calcification is a strong predic-
tor of coronary events and this is a process that is regulated actively by vitamin 
K dependent proteins which are called matrix Gla proteins. There are currently 
no pharmacological means to improve vascular stiffness and vascular calcifica-
tion. There is growing evidence that vitamin K, a cheap and safe intervention that 
can have beneficial effects on cardiovascular health. Vitamin K straightforward 
administration can reduce the progression of vascular calcification. The biologi-
cal rationale is that supplementation with vitamin K will carboxylate (activate) 
Gla proteins, whose role, among others, is to reduce the progression of vascular 
calcification [30]. Coronary artery calcification which is a significant marker of 
cardiovascular disease is affected by these dependent vitamin K proteins. As it was 
mentioned before vitamin-K deficiency promotes coronary artery calcification [6]. 
In animal studies, MGP removal showed severe progression of vessel calcification 
and this empowered the theory about vitamin K role in this process [31]. The most 
of the clinical trials showed that supplementation with Vitamin K2 (menaquinone) 
had beneficial effects in cardiovascular calcification. But a clinical trial from Shea 
et al. showed that also supplementation with vitamin K1 (phyloquinone) slowed 
the progression of coronary artery calcification. Though its effect was enhanced 
by the parallel administration of vitamin-D and calcium supplements [32]. On the 
other hand, Beulens et al., with a cross-sectional study among 564 post-menopausal 
women reached the conclusion that only high intake of menaquinone is associated 
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with reduced coronary calcification, as it was measured via computed cardiac 
tomography [31]. Also Vossen et al. wanted to study a sample of patients with 
coronary artery disease and follow them up via Agatston calcium score about the 
progression of coronary calcification as long as the individuals were under vitamin-
k supplementation [33]. The Roterdam Study, a prospective population-based 
study, showed in a sample of 7983 men and women aged 55 y and over in a follow up 
to 10 years, that dietary intake of menaquinone had a protective effect against coro-
nary heart disease [18]. Also a meta analysis of 3 US Cohorts, among 3891 patients, 
who measured fasting circulating phyloquinone levels, showed that low phyloqui-
none levels was associated with increased all – cause mortality but not of CVD [32]. 
Many clinical trials as referred above showed a possible correlation between vitamin 
K and increased artery calcification mainly in high risk patients. A systematic 
review from Hartley et al. tried to show if there is primary prevention from CVD in 
healthy individuals who received supplementation with vitamin K. They only found 
a small clinical trial with only 60 patients that fulfilled their criteria and there was 
no significant impact in primary prevention of CVD and other CVD factors such 
as blood pressure and plasma lipids level (Hartley). However, this was a small 
clinical trial with short duration. Further studies are necessary about the benefit of 
vitamin-k supplementation in the primary prevention of CVD.
7. Vitamin-K and valvular calcification
Valvular calcification is a common degenerative disease characterized by 
progressive valvurar calcification. Nowadays the incidence of valvural disease is 
higher probably due to increased life expectancy. The most commonly calcified 
valves is aortic valve followed by mitral valve. Based on the role of vitamin K as 
protective agent for cardiovascular health and especially as a protector against 
vascular calcification, some trials evaluated the potential effect of vitamin-k as a 
protective factor against the development of valvular calcification. Bradenburg 
et al. with a small prospective, open label clinical trial with 99 patients, selected 
individuals with asymptomatic or mild symptoms with aortic calcified valve and 
separated them in two study arms with vitamin-k1 supplementation and placebo. 
Then, they calculated the amount of calcification of the valve via cardiac computed 
tomography, at the beginning of the trial and after 12 months. Also they measured 
the dephosphorylated undecarboxylated MGP as a circulating marker for vitamin-
k deficiency. Over the 12 month period, aortic valve calcification volume score 
progressed 10% in the arm with vitamin K supplementation compared with 22% 
in the placebo group. Also plasma dp-ucMGP were significantly reduced by 45% 
in the vitamin K group. On the other hand, this trial had many limitations such as 
the small sample, the short duration of follow up, the open-label design and the 
broad spectrum of severity of valvural disease at baseline [34]. Another clinical 
trial that is planned and want to study the effect of vitamin K in aortic calcification 
is from Peeters et al. concerning especially the calcification progress of bicuspid 
aortic valve. Bicuspid aortic valve, a common congenital abnormality, occurring in 
13,7 per 1000 people in general population is associated with early development of 
calcific aortic valve stenosis. In this double-blind study they will supply vitamin K2 
and follow up 44 people in a period over 18 months. The follow up of the sample 
will be every 6 months with PET/cardiac MRI, cardiac CT and echocardiography. 
This trial will provide us with more information for calcium activity on aortic 
valve and the potential effect of vitamin K. It will also open the way for large scale 
randomized clinical trials in order to develop potential treatment option against the 
progression of calcific aortic valve stenosis [35].
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8. Vitamin-k supplementation and vascular calcification
Vitamin-K deficiency is associated with low-levels of MGP and Gas-6 and the 
accumulation of GRP, ucMGP and dpMGP forms in soft tissues and vessels. As 
it was described before, vitamin-K is used as co-factor for the post-translational 
γ-carboxylation of MGP and Gas-6 in order to maintain preventive effect on vessels 
and VSMCs respectively. In addition, vitamin-k deficiency is associated with higher 
circulating levels of uncarboxylated or dephosphorylated forms of MGP. A three 
arm randomized controlled trial assessed the levels of deposhpo-carboxylated MGP 
levels after 12 weeks of menaquinone-7 supplementation. The dp-ucMGP levels 
were reduced significantly. It is important to mention that according to the authors 
the outcome was dose-dependent and increased in time [4]. In a systematic review 
meta-analysis of trials with different study-design by Lees et al., dp-ucMGP levels 
were significantly reduced with the administration of vitamin-k. However, that 
effect did not lead to the improvement of vascular calcification with the exception 
of a small number of studies. Concerning the use of dp-ucMGP as biomarker of 
CVD the results are controversial and so that is not suggested. It is important to 
mention that the greater efficacy was achieved with vitamin-k2 supplementation 
rather than k1 [30]. These data suggest that dp-ucMGP could be an important 
marker of vitamin-k status. It is worth mentioning that the co-administration of 
vitamin-k and vitamin-D have showed some promising results concerning the 
prevention of fatal CVD. However, larger randomized controlled trials are needed 
in order to delineate if vitamin-k supplementation alone or in combination with 
vitamin-D could benefit patients with progressive vascular calcification [36] 
(Table 1).
Vitamin-K sufficiency Vitamin-K deficiency  




↑ active cMGP prevents:
1. The hydroxyapatite  
formation
2. The accumulation of 
calcium crystals
3. Transdifferentiation of 
VSMCs into osteoblast 
like-cells
4. Decreased BMP-2 activity
Significantly lower levels of MGP-2 and 
accumulation of its inactive forms  





1. Activation of anti-apoptotic 
protein Bcl-2
2. Inhibition of pro-apoptotic 
protein Caspase-3.*
↓Gas-6 levels, inhibition of VSMCs 
growth and increased apoptosis
VSMCs Inhibition of apoptosis 
and transdifferention into 
osteoblast like-cells
Increased apoptosis and 
transdifferention into osteoblast 
like-cells
Vascular Calcification Suspended and possibly 
reversed medial VC**
Increased medial VC
VSMCs status and progression of vascular calcification depending on vitamin-k serum levels. Abbreviations: MGP, 
matrix GIa protein; Gas-6 protein, growth arrest specific gene 6 protein; VSMCs, vascular smooth muscle cell; VC, 
vascular calcification.
*Apoptotic cells are used as substrate for accumulation of calcium crystals.
**Observed in small trials with co-administration with vitamin D. Further studies are needed.
Table 1. 
Summary of changes in vitamin-k dependent proteins.
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9. Conclusion
Vitamin-k is a fat-soluble vitamin mostly known for its significant role in the 
coagulation sequence of steps. However, vitamin-k is also important to other also 
important metabolic pathways. Vascular calcification has proved to be a multi-facto-
rial procedure that leads to the transdifferentation of VSMCs into osteoblast pheno-
type like-cells and a vicious circle of arterial wall calcification. Vitamin-K dependent 
proteins MGP, GRP and Gas-6 play an important role in the regulation of this 
constant progressive process. In cases of vitamin-k deficiency, the preventive effect 
of those Gla proteins on the arterial wall declines and consequently the process of 
vascular calcification is enhanced. The calculation of the uncarboxylated and dephos-
phorylated forms of those proteins are considered a marker of vitamin-k deficiency. 
However, existing data do not suggest the use of dp-ucMGP as predicting factors 
of cardiovascular disease. Vitamin-k supplementation have been associated with a 
significant reduction in the dp-uc MGP circulating levels, although this reduction was 
not related with a reduction in the process of vascular calcification. Due to the multi-
factorial process for the formation of calcified plagues, it cannot be suggested at this 
point that vitamin-k supplementation alone will reverse those lesions. Emerging evi-
dence support the co-administration of vitamin-D and vitamin-K has a greater effect 
against the progression of vascular calcification. Concerning the effect of vitamin-k 
deficiency and cardiovascular health, evidence remains controversial. It is a given 
that more studies are needed in this area in order to draw safe and robust conclusions. 
Vascular calcification and atherosclerotic plaques are strongly related with arterial 
stiffness, hypertension and impaired cardiac function. It is of outmost importance to 
find solution of this degenerative procedure in order to develop additional preventive 
and therapeutic strategies against the development of cardiovascular diseases.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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